---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-035667"
form_type: "8-K"
ticker: "QCLS"
cik: "0001321834"
company_name: "Q/C TECHNOLOGIES, INC."
filed_at: "2023-10-04T23:59:59+00:00"
generated_at: "2026-06-10T04:36:15.490971+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# MyMD reports updated Phase 2 data for MYMD-1 in sarcopenia; TNF-α reduction statistically significant at 1050mg

## Summary
- Cohort 4 (1050mg) showed reduction in TNF-α over 28 days vs placebo (p=0.002 to 0.008).
- Phase 2 study met all primary PK and secondary safety/tolerability endpoints across multiple doses.
- FDA accepted IND for MYMD-1 in rheumatoid arthritis; Phase 2 trials planned.
- Company plans to present clinical safety report to FDA and seek guidance for Phase 3 trial in sarcopenia.

## SEC filing metadata
- accession: 0001493152-23-035667
- form_type: 8-K
- ticker: QCLS
- cik: 0001321834
- company_name: Q/C TECHNOLOGIES, INC.
- filed_at: 2023-10-04T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1321834/000149315223035667/0001493152-23-035667-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1321834/000149315223035667/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-035667
- JSON: https://secwatch.observer/filing/0001493152-23-035667.json
- Plain text: https://secwatch.observer/filing/0001493152-23-035667.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.